Hawaii Clinical Trials

A listing of Hawaii Clinical Trials actively recruiting patient volunteers.

Beloved as an island paradise, Hawaii actually consists of eight major islands that are home to about 1.4 million people. Because of the archipelago's layout, large cities tend to be separated. Honolulu, on Oahu, is the largest city and the capital. Kailua-Kona and Hilo are some of the other major cities. Hawaii has long had a tourism-friendly economy where visitors from around the world can visit breathtaking white sand beaches, tour volcanoes, and see waterfalls. The Queen's Medical Center, part of The Queen's Health Systems, is the largest private hospital in the state, supporting more than 570 acute care beds.

Search by Name
Search
Filter by Condition
265 trials found

A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting

NCT05348733

This is an observational study in people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone. Kidneys filter extra water and waste out of the blood and make urine. CKD is a long-term, progressive, decrease in the kidneys' ability filter the blood properly. In people with T2D, the body does not make enough of a hormone called insulin, or does not use insulin well enough, resulting in high blood sugar levels that can cause damage to the kidneys. As a resul ...

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus

A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80

NCT05348785

In this study, researchers will learn more about a study drug called BIIB122 in participants with early-stage Parkinson's disease (PD). In this study: Participants will take 225 milligrams (mg) of BIIB122 or a placebo as tablets by mouth. A placebo looks like the study drug but has no real medicine in it. Participants will take BIIB122 or placebo 1 time a day for up to a minimum of 48 weeks and a maximum of 144 weeks. Certain medications for PD will be allowed at enrollment for a subset of part ...

Conditions: Parkinson Disease

Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

NCT05364021

The objective of this study is to assess the safety, tolerability, efficacy, and pharmacokinetics of adjunctive therapy of LP352 in adults and adolescents with developmental and epileptic encephalopathies.

Conditions: Developmental and Epileptic Encephalopathy, Dravet Syndrome, Lennox Gastaut Syndrome
Phase: Phase 1/2

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis

NCT05369546

The objective is to better identify suspicious breast lesions that need to be biopsied for malignancy in women currently recommended for biopsy. The long-term goal is to reduce unnecessary biopsies and increase biopsy yield. To do this, we have developed an innovative way to use FDA-approved breast imaging protocols to acquire multispectral images to measure the composition of suspicious breast lesions. Our central hypothesis is that breast tissue composition in combination with analysis of morp ...

Conditions: Breast Cancer

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool

NCT05386355

This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19). The hypothesis is that unvaccinated children of caregivers assigned to the Vaccine Uptake app will be more likely to achieve COVID-19 vaccine series completion than those children whose caregivers are assigned to the General Health app.

Conditions: COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
Phase: Not Applicable

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD

NCT05407636

RGX-314 is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. Wet AMD is a significant cause of vision loss in the United States, Europe and Japan, with up to 2 million people living with wet AMD in these geographies alone. Current anti-VEGF therapies have significantly changed the landscape for treatment of wet AMD, b ...

Conditions: AMD, nAMD, Wet Age-related Macular Degeneration, wAMD, WetAMD, CNV

OTT166 in Diabetic Retinopathy (DR)

NCT05409235

This study will evaluate the safety and efficacy of OTT166 Ophthalmic solution in participants with Diabetic Retinopathy.

Conditions: Diabetic Retinopathy

A Study of LY3209590 Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy

NCT05463744

The main purpose of this study is to measure the safety and efficacy of LY3209590 compared with insulin degludec in participants with type 1 diabetes treated with multiple daily injection therapy.

Conditions: Type 1 Diabetes, Diabetes

A Study to Learn About New COVID-19 RNA Vaccine Candidates as a Booster Dose in COVID-19 Vaccine-Experienced Healthy Individuals

NCT05472038

The purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b, RNA-based SARS-CoV-2 vaccine candidates given as a booster dose in adults to prevent COVID-19. For all cohorts (groups of participants), this study is seeking participants who are healthy (who may have preexisting disease if it is stable); All participants will receive a single dose of the study vaccine at the first study clinic and will return to the study clinic at least 4 more times. ...

Conditions: SARS-CoV-2 Infection, COVID-19

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

NCT05489887

This is a prospective, multicenter clinical trial in subjects with newly diagnosed high-risk neuroblastoma to evaluate the efficacy and safety of administering naxitamab with standard induction therapy. The initial chemotherapy will include 5 cycles of multi-agent chemotherapy. Naxitamab will be added to all 5 Induction cycles. Subjects with an ALK mutation or amplification will have ceritinib added to their treatment regimen as soon as results are available. We hypothesize that the addition of ...

Conditions: High-risk Neuroblastoma

Natives Engaged in Alzheimers Research - 'Ike Kupuna

NCT05534607

This study will conduct a group randomized trial to test the effects of a hula-based intervention in improving vascular risk factors for ADRD and cognitive complaints and function over 12 months.

Conditions: Mild Cognitive Impairment, Subjective Cognitive Impairment
Phase: Not Applicable

Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration

NCT05536973

Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of blindness in patients over 65 years of age. The abnormal angiogenic process in nAMD is stimulated and modulated by vascular endothelial growth factor (VEGF). Treatment of nAMD requires frequent intravitreal (IVT) injections of VEGF inhibitors (anti-VEGF) administered every 4 ...

Conditions: Neovascular Age-related Macular Degeneration